-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
South Korea Launches Probe into NewJeans Contract Controversy
-
Met Office Issues Yellow Snow Warning for Nottinghamshire on Tuesday
-
UK Defence Secretary Warns Russia Nukes Not for Negotiation as HMS Vengeance Returns
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
-
OBI Pharma Signs Collaboration and License Agreement with Novartis
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 16
-
Blue Chip Capital Group Announces Quotation of its Common Stock on the OTCID and Updates Status of Initial Regulatory Compliance
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
Emerging Growth Research Highlights Criticality of First Phosphate G7-Backed LFP Battery Onshoring Solution as Cleantech Sector Accelerates Post U.S. Midterms
-
Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended September 30, 2026
-
Sekur Private Data Ltd. Provides Update on Expected Closing of Non-Brokered Private Placement
-
iFabric Corp Announces Record Revenues for Q3 2026 and the Nine Months Ended September 30, 2026
-
RenX Enterprises Reports Record Third Quarter Revenue of $4.49 Million, Up 27.6% Year Over Year
-
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
-
Gladstone Capital Corporation Earnings Call and Webcast Information
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
Poll Shows Two-Thirds of New York Voters Support Lifting Charter School Cap
-
Park Jin-young Denies Cult Allegations Against Firstfruits Group
-
Downing Street Defends PM's Speechwriting After AI Photo Emerges
OBI Pharma Signs Collaboration and License Agreement with Novartis
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies.
Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes.
This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, and GlycOBI DUO®, and supports OBI's strategy of expanding the global application of its ADC technologies through strategic agreements.
Ya-Chi Chen, Pharm.D., acting Chief Executive Officer of OBI Pharma, Inc., commented: "We are delighted to enter into this agreement with Novartis, a leading pharmaceutical company in innovative oncology drug development with extensive commercialization capabilities. This agreement recognizes the scientific and commercial potential of OBI's proprietary ADC technologies and reflects the value of our differentiated platform. By combining OBI's ADC expertise with Novartis's resources and capabilities, we aim to advance next-generation therapies that could deliver meaningful benefits to patients."
"Engaging with OBI's expertise and technologies in antibody-drug conjugation to create potential ADCs with novel payloads is an important part of our oncology ADC strategy. This collaboration supports our ambition to innovate novel therapies and potentially expand treatment options for patients," said Shiva Malek, Global Head of Oncology, Biomedical Research at Novartis.
Under the terms of the agreement, OBI will receive an upfront payment of USD 30 million and is eligible to receive development, regulatory and commercial milestone payments for a total potential deal value exceeding USD 2 billion. In addition, OBI is eligible to receive tiered royalties on net sales of the licensed products resulting from the collaboration.
About Obrion® ADC Technology
OBI has developed the proprietary Obrion® ADC Technology Platform, which integrates multiple ADC-enabling technologies to support the development of next-generation ADCs. At the core of Obrion® is GlycOBI®, a glycan-based conjugation technology with a flexible, plug-and-play design compatible with a broad range of antibodies, linkers, and payloads, while supporting different drug-to-antibody ratios (DARs).
Powered by OBI's proprietary dual-function enzymatic technology, EndoSymeOBI®, and highly hydrophilic and stable linker technology, HYPrOBI®, GlycOBI® enables the efficient and scalable production of site-specific, homogeneous ADCs under GMP conditions. GlycOBI DUO® further expands the capabilities of the Obrion® platform by enabling next-generation ADC modalities, including dual-payload ADCs.
About OBI Pharma
OBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan, with operations in the United States and Australia. The company is focused on developing innovative cancer therapeutics and advancing proprietary antibody-drug conjugate (ADC) technologies to address unmet medical needs and provide new treatment options for patients.
Forward-Looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.
COMPANY CONTACT:
Jukka Muhonen
Executive Director, Business Development
OBI Pharma USA, Inc.
email: [email protected]
tel.: +1 617 821 0292
SOURCE: OBI Pharma, Inc.
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN